India, Aug. 28 -- The Government of India has issued a release:
The Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers has announced the second call for applications under the Promotion of Research and Innovation in Pharma & MedTech (PRIP) Scheme. The Scheme with a financial outlay of Rs. 5,000 crore aims to strengthen India's Pharma and MedTech research and development ecosystem by supporting startups, MSMEs, and large companies to leapfrog up the innovation value chain.
Applications are invited across two tracks:
Application forms and supporting guidance are available on the PRIP portal: https://prip.pharma-dept.gov.in/. Applicants can also refer to the following resources for details on the application requirements:
The submission window on PRIP portal will open by mid-September. Applicants who had submitted projects under PRIP Round 1 have been asked not to resubmit the same project. For any queries, interested applicants can write to support-prip@pharma-dept.gov.in.
PRIP scheme was launched in 2023 with a view to promote research and development in the Pharmaceutical sector, including in the areas of artificial intelligence (AI) and machine learning. It seeks to build world-class research infrastructure and deepen the talent pool of qualified, trained students. With a view to enhance the prospects of commercialisation of viable outputs, industry and startups can also take advantage of mentorship support that will be provided under the Scheme. Initiatives such as MedTech Mitra and Patent Mitra and the online platform under the Scheme will facilitate collaboration and partnership among various stakeholders.
Following are the identified priority areas under the scheme.
1. New Medicines - new chemical medicines/substances (including new chemical Entity (NCE), New Biological Entity (NBE) and Phyto-pharmaceuticals)
2. Complex Generics and Biosimilars
3. Novel medical devices (Targeted Innovative Therapeutics) - This refers to medical devices that have not been previously approved by CDSCO. It covers all novel medical devices, including the following: (i) AI/ML based medical devices with software development, Software as Medical Device (SaMD) and Software in Medical Device (SiMD); (ii) Medical diagnostics and screening devices with genetic technology; (iii) Robotic medical devices for surgical procedures; (iv) Medical devices with telemedicine facilities; and (v) Any novel in vitro diagnostic medical device, including biomarkers, that enables precision medicine.
Disclaimer: Curated by HT Syndication.
